This study is designed to evaluate the safety and tolerability of a single dose of an investigational drug, alogliptin, in children and adults with type 2 diabetes.
To qualify for this clinical trial, you must meet the following eligibility requirements:
Participation requires one or two screening visits, a three-day, two-night stay, and two follow-up outpatient visits.
The study will take place at the Duke Clinical Research Unit.
Participants will receive payment for time and travel.
For more information, contact Duke Clinical Research Unit at 919-613-6246.